| Website | vivendy.ch |
| Category | BioTech |
| Phone | +41-61-271 87 80 |
| Employees | |
| Description | Enzyme Replacement |
| Unattributed, 1/08 Aescap Venture TVM Capital | $30.5M |
Vivendy Therapeutics Ltd. has developed a specific recombinant human N-acetylgalactosamine-6-sulfatase (rhGALNS) that is specifically modified to improve enzyme activity - enhancing the efficacy of the therapy in MPS IVA significantly